1. Inici
  2. Projectes i Estudis Clínics
  3. Interventional, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of intravenous (IV) eptinezumab in paediatric patients (6 to 17 years) for the preventive treatment of episodic migraine.

Interventional, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of intravenous (IV) eptinezumab in paediatric patients (6 to 17 years) for the preventive treatment of episodic migraine.

Dades bàsiques

Protocol:
19357A
EURDRACT:
2022-502538-14-00
NCT:
Centre:
HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
Any inici:
2023
Any de finalització:
ENSAYO CLÍNICO

Documents

  • No hi ha documents

Participants

Grups d'Investigació

Finançadors - Promotors

H. LUNDBECK A/S

Resultats de l'Assaig Clínic

[Translated article] Knowledge of biological therapy in patients with immune-mediated diseases. BIOINFO study.

Segui-Solanes, Carlos; (...); Borras-Blasco, Joaquin

Article. 10.1016/j.farma.2024.08.002. 2024

  • Open Access.

[Translated article] New challenges in advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2024.05.001. 2024

  • Open Access.

[Translated article] Pharmacokinetic-guided switching from standard half-life factor VIII to extended half-life pegylated factor VIII in haemophilia A therapy in clinical practice.

Chovi-Trull, Maria; (...); Andres, Jose Luis Poveda

Article. 10.1016/j.farma.2024.12.007. 2025


Benefits of physical activity self-monitoring in patients with haemophilia: a prospective study with one-year follow-up.

Pérez-Alenda S; (...); Núñez-Cortés R

Article. 10.1111/hae.14988. 2024

  • Open Access.

Burden of Episodic and Chronic Migraine in Patients Who Had Failed Multiple Preventive Treatments From France, Spain, and the United Kingdom

Diaz-Insa, Samuel; (...); Goadsby, Peter J.

Article. 10.1155/ane/4714514. 2024

  • Open Access.

Cluster headache. Are there differences by gender?

Olivier, M. A.; (...); Diaz Insa, S.

Meeting Abstract. 2024

  • Open Access.

Cost-effectiveness and cost-utility analysis of haemate-P versus other von willebrand disease treatments in Spain.

Megias-Vericat, Juan E; (...); Yan, Songkai

Article. 10.1080/13696998.2025.2474886. 2025


Development and testing of a mobile app for systematic collection of patient-reported outcomes (PROs) in patients with hemophilia.

Megias-Vericat, J E; (...); Poveda Andres, J L

Letter. 10.1016/j.thromres.2024.109122. 2024


Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology's Headache Study Group

Garcia-Ulla, J.; (...); Irimiao, P.

Article. 10.1016/j.nrl.2023.06.003. 2025

  • Open Access.

Diagnosis and treatment of disorders of intracranial pressure: consensus statement of the Spanish Society of Neurology's Headache Study Group.

Garcia-Ull, J; (...); Irimia, P

Practice Guideline. 10.1016/j.nrleng.2024.02.009. 2024

  • Open Access.

Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers

Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo

Article. 10.3390/ijms241814151. 2023

  • Open Access.

Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients.

Muñoz-Vendrell A; (...); Huerta-Villanueva M

Article. 10.1186/s10194-023-01585-2. 2023

  • Open Access.

Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia

Boluda, Blanca; (...); Montesinos, Pau

Article. 10.3390/cancers15082267. 2023

  • Open Access.

Mental, emotional and social dimensions of quality of life and their relationship with physical and functional status in adults with haemophilia.

Rodríguez MA; (...); Chimeno-Hernández A

Article. 10.1016/j.thromres.2024.109181. 2024

  • Open Access.

New challenges of advanced therapies.

Megías-Vericat JE; (...); Poveda Andrés JL

Article. 10.1016/j.farma.2023.11.008. 2024

  • Open Access.

Nueva era terapéutica para el ataque de migraña con los recientemente aprobados anticuerpos monoclonales, ditanes y gepantes.

Mínguez-Olaondo A; (...); Díaz-Insa S

Article. 10.33588/rn.7802.2023176. 2024

  • Open Access.

Observational Retrospective Study in Patients Treated with Galcanezumab as Preventive Treatment for Migraine: The ORYGAM Study.

Díaz Insa S; (...); Núñez M

Article. 10.1007/s40122-024-00586-6. 2024

  • Open Access.

Onabotulinum Toxin A (OnA) as a preventive treatment for non-migraine headaches: a retrospective analysis

Nieves Castellanos, C.; (...); Diaz Insa, S.

Meeting Abstract. 2024

  • Open Access.

Pharmacogenetics in Response to Biological Agents in Inflammatory Bowel Disease: A Systematic Review.

Ballesta-Lopez, Octavio; (...); Poveda-Andres, Jose Luis

Article. 10.3390/ijms26041760. 2025

  • Open Access.

Predictors of =50% and =75% response to anti-CGRP monoclonal antibodies for migraine prevention in real life: results from a european multicenter observational study including 5818 patients

Caronna, E.; (...); Pozo-Rosich, P.

Meeting Abstract. 2024


Psychological intervention in refractory chronic migraine patients

Zambrano Camina, M.; (...); Diaz Insa, S.

Meeting Abstract. 2024


Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world.

Caronna E; (...); Pozo-Rosich P

Article. 10.1136/jnnp-2023-333295. 2024

  • Open Access.

Toxic-metabolic encephalopathy induced by metronidazole and disulfiram: classics never die.

Chovi-Trull, Maria; (...); Poveda-Andres, Jose Luis

Article. 10.1136/ejhpharm-2024-004184. 2024


Campos d'Estudi

Compartir el projecte